title: No difference in markers of adipose tissue inflammation between overweight women with polycystic ovary syndrome and weight-matched controls.
abstract: BACKGROUND; Previous studies have indicated that peripheral circulating markers of inflammation are elevated in women with polycystic ovary syndrome (PCOS), but thus far no studies concerning markers of inflammation in adipose tissue have been published. The aim of the study was to investigate whether patients with PCOS display increased expression of inflammatory markers in adipose tissue.
  
  
  METHODS
  Twenty overweight patients with PCOS, 10 lean patients with PCOS and 20 overweight controls had subcutaneous fat biopsies and blood samples taken. Adipose tissue levels of mRNA of inflammatory markers were determined by use of real-time PCR.
  
  
  RESULTS
  Overweight patients with PCOS had higher relative adipose tissue chemokine ligand 2 (P < 0.01), and its cognate receptor (P < 0.05), tumour necrosis factor-α (P < 0.001), interleukin (IL)-10 (P < 0.001) and IL-18 (P < 0.001) and the monocyte/macrophage markers CD14 (P < 0.01) and CD163 (P < 0.01) mRNA levels compared with lean women with PCOS. There were no differences between overweight patients with PCOS and overweight control subjects in this respect. Within the PCOS group, markers of adipose tissue inflammation correlated significantly with obesity-related metabolic disturbances, but when data were adjusted for age and BMI, most correlations were lost.
  
  
  CONCLUSIONS
  Overweight, rather than the PCOS diagnosis per se, appears to be the main explanatory variable for elevated adipose tissue inflammation in patients with PCOS.
authors.affiliation: Department of Women's and Children's Health, Uppsala University, Uppsala, Sweden. asa.lindholm@nll.se
authors.forename: Asa
authors.initials: A
authors.lastname: Lindholm
authors.forename: Caroline
authors.initials: C
authors.lastname: Blomquist
authors.forename: Marie
authors.initials: M
authors.lastname: Bixo
authors.forename: Ingrid
authors.initials: I
authors.lastname: Dahlbom
authors.forename: Tony
authors.initials: T
authors.lastname: Hansson
authors.forename: Inger
authors.initials: I
authors.lastname: Sundström Poromaa
authors.forename: Jonas
authors.initials: J
authors.lastname: Burén
mesh_terms: D000328:Adult; D015703:Antigens, CD / Q000097:blood; D015214:Antigens, Differentiation, Myelomonocytic / Q000097:blood; D015415:Biomarkers / Q000097:blood*; D018932:Chemokine CCL2 / Q000097:blood; D005260:Female; D006801:Humans; D007249:Inflammation / Q000097:blood*; D016753:Interleukin-10 / Q000097:blood; D020382:Interleukin-18 / Q000097:blood; D018950:Lipopolysaccharide Receptors / Q000097:blood; D050177:Overweight / Q000097:blood*; D011085:Polycystic Ovary Syndrome / Q000097:blood*; D012333:RNA, Messenger / Q000378:metabolism; D054390:Receptors, CCR2 / Q000097:blood; D011956:Receptors, Cell Surface / Q000097:blood; D050151:Subcutaneous Fat / Q000378:metabolism*; D014409:Tumor Necrosis Factor-alpha / Q000097:blood; D000098902:CD163 Antigen
chemical_list: D015703:Antigens, CD; D015214:Antigens, Differentiation, Myelomonocytic; D015415:Biomarkers; C111835:CCL2 protein, human; D000098902:CD163 Antigen; D018932:Chemokine CCL2; C508609:IL10 protein, human; D020382:Interleukin-18; D018950:Lipopolysaccharide Receptors; D012333:RNA, Messenger; D054390:Receptors, CCR2; D011956:Receptors, Cell Surface; D014409:Tumor Necrosis Factor-alpha; D016753:Interleukin-10